Psychosis Australia is urging the TGA to update clozapine monitoring to reflect current evidence and improve safety, access, and consumer experience.

We recommend:

• Modern ANC thresholds to reduce unnecessary treatment stops and ensure culturally safe care.

• Simpler monitoring, with reduced ANC testing after the first two years.

• Stronger adverse-effect monitoring through regular physical health checks.

• Better shared-care, with GPs leading quarterly monitoring and psychiatrists reviewing care annually.

• Clear, consumer-centred education at key points in treatment.

These changes will improve safety, reduce hospitalisations, and make clozapine more accessible for people with treatment-resistant schizophrenia.